Radiobiological effect of 131I radiolabeled recombinant human epidermal growth factor on nude mice with human breast cancer / 生物医学工程学杂志
Journal of Biomedical Engineering
; (6): 749-753, 2005.
Article
in Zh
| WPRIM
| ID: wpr-238349
Responsible library:
WPRO
ABSTRACT
The radiobiological effect of 131I radiolabeled recombinant human epidermal growth factor (131I-rhEGF) on nude mice with human breast cancer was assessed in this study. The tissue mainly uptaking 131I-rhEGF was found by tissue distribution assay in mice. The radiation breakdown of the tissue greatly collecting 131I-rhEGF was examined by biochemical test and biopsy in nude mice with human breast cancer. The tissue distribution assay of 131I-rhEGF in mice showed that 131I-rhEGF greatly accumulated in kidney, liver, spleen and blood. The biochemical test and biopsy revealed that 131I -rhEGF injected twice (dosing once is analogous to 14.58 GBq in a person with 50 kg, once every 14 days) had an effective killing effect on tumor but had no effect of radiation breakdown on kidney, liver,spleen and blood-cell forming tissue in mice with human breast cancer. Therefore, 131I-rhEGF is a drug unharmful to normal tissues in the course of the receptor-mediated target radiotherapy for breast cancer.
Full text:
1
Index:
WPRIM
Main subject:
Pathology
/
Radiotherapy
/
Recombinant Proteins
/
Breast Neoplasms
/
Pharmacokinetics
/
Random Allocation
/
Drug Delivery Systems
/
Radiopharmaceuticals
/
Cell Line, Tumor
/
Therapeutic Uses
Type of study:
Clinical_trials
Limits:
Animals
/
Humans
Language:
Zh
Journal:
Journal of Biomedical Engineering
Year:
2005
Type:
Article